{"id":"W3214579091","doi":"10.1182/blood-2021-147417","title":"Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Anagrelide; Internal medicine; Clinical endpoint; Essential thrombocythemia; Randomized controlled trial; Hydroxycarbamide; Clinical trial; Surgery; Adverse effect; Polycythemia vera; Oncology; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002618975,0.001474144,0.002268437,0.0002524049,0.0003257177,0.001230818,0.000763089,0.001291699,0.006474161],"category_scores_gemma":[0.001447882,0.0004612328,0.001399964,0.0003063786,0.0009113729,0.001601085,0.0003880491,0.002899388,0.0008473937],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006704294,"about_ca_system_score_gemma":0.0009420962,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000437787,"about_ca_topic_score_gemma":0.0009719618,"domain_scores_codex":[0.9994049,0.0003046558,0.00003383728,0.0001200004,0.00006369455,0.00007283303],"domain_scores_gemma":[0.9990482,0.0002269142,0.0002705191,0.00007219794,0.00006579856,0.0003164569],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9638485,0.007656474,0.001406792,0.0008796468,0.001344741,0.00007271645,0.00006763539,0.0005055066,0.005066413,0.0003385474,0.001745102,0.01706793],"study_design_scores_gemma":[0.9219661,0.07177509,0.002843424,0.00003904598,0.0005196172,0.0001094054,0.00002900538,0.0007765738,0.0004428239,0.0002596877,0.001221066,0.00001822272],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9825693,0.006371079,0.001084101,0.0009069245,0.0003698569,0.003657621,0.002147929,0.0002009028,0.002692273],"genre_scores_gemma":[0.9788352,0.003016993,0.00282915,0.002049124,0.0004895673,0.005131437,0.00367673,0.00005217064,0.003919664],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006474161,"threshold_uncertainty_score":0.02165824,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06692123825267011,"score_gpt":0.4178400961955688,"score_spread":0.3509188579428987,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}